Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
-
Published:2024-07
Issue:
Volume:154
Page:106866
-
ISSN:1368-8375
-
Container-title:Oral Oncology
-
language:en
-
Short-container-title:Oral Oncology
Author:
Park RobinORCID,
Li Jiannong,
Slebos Robbert J.C.,
Chaudhary Ritu,
Poole Maria I.,
Ferraris Carina,
Farinhas Joaquim,
Hernandez-Prera Juan,
Kirtane Kedar,
Teer Jamie K.,
Song Xiaofei,
Hall MacLean S.,
Tasoulas Jason,
Amelio Antonio L.,
Chung Christine H.
Reference50 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023
2. Head and neck cancer: changing epidemiology, diagnosis, and treatment;Marur;Mayo Clin Proc,2008
3. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. Jul 15 2019;7(1):184. doi: 10.1186/s40425-019-0662-5.
4. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study;Harrington;J Clin Oncol,2022
5. The changing therapeutic landscape of head and neck cancer;Cramer;Nat Rev Clin Oncol,2019